These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 22270369)

  • 1. Absence of post-phosphoryl modification in dystroglycanopathy mouse models and wild-type tissues expressing non-laminin binding form of α-dystroglycan.
    Kuga A; Kanagawa M; Sudo A; Chan YM; Tajiri M; Manya H; Kikkawa Y; Nomizu M; Kobayashi K; Endo T; Lu QL; Wada Y; Toda T
    J Biol Chem; 2012 Mar; 287(12):9560-7. PubMed ID: 22270369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDP-glycerol inhibits the synthesis of the functional
    Imae R; Manya H; Tsumoto H; Osumi K; Tanaka T; Mizuno M; Kanagawa M; Kobayashi K; Toda T; Endo T
    J Biol Chem; 2018 Aug; 293(31):12186-12198. PubMed ID: 29884773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Residual laminin-binding activity and enhanced dystroglycan glycosylation by LARGE in novel model mice to dystroglycanopathy.
    Kanagawa M; Nishimoto A; Chiyonobu T; Takeda S; Miyagoe-Suzuki Y; Wang F; Fujikake N; Taniguchi M; Lu Z; Tachikawa M; Nagai Y; Tashiro F; Miyazaki J; Tajima Y; Takeda S; Endo T; Kobayashi K; Campbell KP; Toda T
    Hum Mol Genet; 2009 Feb; 18(4):621-31. PubMed ID: 19017726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Recent Advances in α-dystroglycanopathy].
    Kuga A; Kanagawa M; Toda T
    Brain Nerve; 2011 Nov; 63(11):1189-95. PubMed ID: 22068471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HNK-1 sulfotransferase-dependent sulfation regulating laminin-binding glycans occurs in the post-phosphoryl moiety on α-dystroglycan.
    Nakagawa N; Takematsu H; Oka S
    Glycobiology; 2013 Sep; 23(9):1066-74. PubMed ID: 23723439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential glycosylation of α-dystroglycan and proteins other than α-dystroglycan by like-glycosyltransferase.
    Zhang P; Hu H
    Glycobiology; 2012 Feb; 22(2):235-47. PubMed ID: 21930648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin alpha2 deficiency and abnormal glycosylation of alpha-dystroglycan.
    Brockington M; Blake DJ; Prandini P; Brown SC; Torelli S; Benson MA; Ponting CP; Estournet B; Romero NB; Mercuri E; Voit T; Sewry CA; Guicheney P; Muntoni F
    Am J Hum Genet; 2001 Dec; 69(6):1198-209. PubMed ID: 11592034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prenatal muscle development in a mouse model for the secondary dystroglycanopathies.
    Kim J; Hopkinson M; Kavishwar M; Fernandez-Fuente M; Brown SC
    Skelet Muscle; 2016; 6():3. PubMed ID: 26900448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impaired viability of muscle precursor cells in muscular dystrophy with glycosylation defects and amelioration of its severe phenotype by limited gene expression.
    Kanagawa M; Yu CC; Ito C; Fukada S; Hozoji-Inada M; Chiyo T; Kuga A; Matsuo M; Sato K; Yamaguchi M; Ito T; Ohtsuka Y; Katanosaka Y; Miyagoe-Suzuki Y; Naruse K; Kobayashi K; Okada T; Takeda S; Toda T
    Hum Mol Genet; 2013 Aug; 22(15):3003-15. PubMed ID: 23562821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. O-mannosyl phosphorylation of alpha-dystroglycan is required for laminin binding.
    Yoshida-Moriguchi T; Yu L; Stalnaker SH; Davis S; Kunz S; Madson M; Oldstone MB; Schachter H; Wells L; Campbell KP
    Science; 2010 Jan; 327(5961):88-92. PubMed ID: 20044576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Muscular Dystrophy Gene TMEM5 Encodes a Ribitol β1,4-Xylosyltransferase Required for the Functional Glycosylation of Dystroglycan.
    Manya H; Yamaguchi Y; Kanagawa M; Kobayashi K; Tajiri M; Akasaka-Manya K; Kawakami H; Mizuno M; Wada Y; Toda T; Endo T
    J Biol Chem; 2016 Nov; 291(47):24618-24627. PubMed ID: 27733679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zebrafish models for human FKRP muscular dystrophies.
    Kawahara G; Guyon JR; Nakamura Y; Kunkel LM
    Hum Mol Genet; 2010 Feb; 19(4):623-33. PubMed ID: 19955119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-terminal domain on dystroglycan enables LARGE1 to extend matriglycan on α-dystroglycan and prevents muscular dystrophy.
    Okuma H; Hord JM; Chandel I; Venzke D; Anderson ME; Walimbe AS; Joseph S; Gastel Z; Hara Y; Saito F; Matsumura K; Campbell KP
    Elife; 2023 Feb; 12():. PubMed ID: 36723429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fukutin-related protein is essential for mouse muscle, brain and eye development and mutation recapitulates the wide clinical spectrums of dystroglycanopathies.
    Chan YM; Keramaris-Vrantsis E; Lidov HG; Norton JH; Zinchenko N; Gruber HE; Thresher R; Blake DJ; Ashar J; Rosenfeld J; Lu QL
    Hum Mol Genet; 2010 Oct; 19(20):3995-4006. PubMed ID: 20675713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endogenous glucuronyltransferase activity of LARGE or LARGE2 required for functional modification of α-dystroglycan in cells and tissues.
    Inamori K; Willer T; Hara Y; Venzke D; Anderson ME; Clarke NF; Guicheney P; Bönnemann CG; Moore SA; Campbell KP
    J Biol Chem; 2014 Oct; 289(41):28138-48. PubMed ID: 25138275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new patient-derived iPSC model for dystroglycanopathies validates a compound that increases glycosylation of α-dystroglycan.
    Kim J; Lana B; Torelli S; Ryan D; Catapano F; Ala P; Luft C; Stevens E; Konstantinidis E; Louzada S; Fu B; Paredes-Redondo A; Chan AE; Yang F; Stemple DL; Liu P; Ketteler R; Selwood DL; Muntoni F; Lin YY
    EMBO Rep; 2019 Nov; 20(11):e47967. PubMed ID: 31566294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Muscular Dystrophy with Ribitol-Phosphate Deficiency: A Novel Post-Translational Mechanism in Dystroglycanopathy.
    Kanagawa M; Toda T
    J Neuromuscul Dis; 2017; 4(4):259-267. PubMed ID: 29081423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dystroglycanopathy muscles lacking functional glycosylation of alpha-dystroglycan retain regeneration capacity.
    Awano H; Blaeser A; Wu B; Lu P; Keramaris-Vrantsis E; Lu Q
    Neuromuscul Disord; 2015 Jun; 25(6):474-84. PubMed ID: 25937147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ribitol restores functionally glycosylated α-dystroglycan and improves muscle function in dystrophic FKRP-mutant mice.
    Cataldi MP; Lu P; Blaeser A; Lu QL
    Nat Commun; 2018 Aug; 9(1):3448. PubMed ID: 30150693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fukutin-Related Protein: From Pathology to Treatments.
    Ortiz-Cordero C; Azzag K; Perlingeiro RCR
    Trends Cell Biol; 2021 Mar; 31(3):197-210. PubMed ID: 33272829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.